AstraZeneca plans to invest $520 million in its manufacturing site in Dunkirk, France, over the next five years and create roughly 150 jobs, Bloomberg reported.
Of the total, $230 million will be dedicated to building assembly lines and modernizing the drugmaker's equipment in the Dunkirk facility, which focuses on developing and manufacturing asthma treatments. The new lines could create about 100 highly skilled jobs, according to Bloomberg.